A Phase 2 interventional study of MK0663, etoricoxib / Duration of Treatment: Part I (6 weeks), Part II (8 weeks) and Placebo;Diclofenac 50mg(tid)/Duration of Treatment: Part I (Placebo) 6 weeks;Part II (Diclofenac) 8 weeks in Osteoarthritis, sponsored by Organon and Co. Completed. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2022-02-18.
Sponsored by Organon and Co · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Osteoarthritis by Organon & Co. — none open to participants now, none under way, none of them phase 3. Osteoarthritis · Organon & Co..
Among the 15 studies in Osteoarthritis by Organon & Co., this one is the 3rd largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 1998, is the only one in phase 2, and was the 6th registered.
2,975 studies on the registry are indexed under Osteoarthritis; 436 are open to participants now.
Browse Osteoarthritis studies →None of the 15 studies in Osteoarthritis by Organon & Co. is open now. The open studies under Osteoarthritis, anywhere →
Of the 285 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 71 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 8 · Phase 4 2
First in 1998; this study’s year is marked. 1 started in 1998.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,167 is above the median of 80 across 2,240 interventional studies indexed under Osteoarthritis.
Median enrollment 508 across the 12 interventional studies, 1,261 across the 3 observational. Of the 14 that completed or were terminated, 4 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Organon and Co, one of the names counted as Organon & Co.. Under that name alone:
Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Osteoarthritis by Organon & Co., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and efficacy of etoricoxib in the treatment of osteoarthritis of the knee.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
WOMAC Pain Subscale, Investigator Global Assessment of Disease Status, and Patient Global Assessment of Response to Therapy (not a primary endpoint in extension periods)
Physical Function Subscale (WOMAC), Stiffness Subscale (WOMAC), Patient Global Assessment of Disease Status, Investigator Global Assessment of Response to Therapy , Proportion of Patients Discontinued Due to Lack of Efficacy
No study locations are listed for this record.
The record gives a start of Jun 1998, a primary completion of Feb 1999 and a completion of Jul 2002. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.